Pharmacogenomics of endocrine therapy in breast cancer

Research output: Chapter in Book/Report/Conference proceedingChapter

20 Citations (Scopus)

Abstract

The treatment of breast cancer with selective estrogen receptor modulators such as tamoxifen and with aromatase inhibitors represents a major advance in cancer chemotherapy. However, there are large variations among patients in both the therapeutic efficacy and side effects of these drugs. Pharmacogenomics is the study of the role of inheritance in this variation and genetic variation in tamoxifen response represents one of the most striking examples of the potential clinical importance of pharmacogenomics. Tamoxifen requires "metabolic activation" catalyzed by cytochrome P450 2D6 (CYP2D6) to form hydroxylated metabolites-4-hydroxytamoxifen and endoxifen (N-desmethyl-4-hydroxytamoxifen)- both of which are much more potent than is the parent drug. However, CYP2D6 is genetically polymorphic. Approximately 5-8% of Caucasian subjects are CYP2D6 "poor metabolizers" on a genetic basis and, as a result, are relatively unable to catalyze tamoxifen hydroxylation. These same subjects appear to have poorer outcomes when treated with tamoxifen than do CYP2D6 "extensive metabolizers". These data led the US Food and Drug Administration (FDA) to hold public hearings in 2006 on the inclusion of this pharmacogenomic information in tamoxifen labeling. However, a series of important questions still remains to be addressed with regard to tamoxifen pharmacogenomics. There have also been preliminary attempts to study the pharmacogenomics of aromatase inhibitors, including the application of a genotype-to-phenotype research strategy designed to explore the nature and extent of common DNA sequence variation in the CYP19 gene that encodes aromatase. Those results-together with our current level of understanding of tamoxifen pharmacogenomics-will be reviewed in this chapter and both will be placed within the context of the overall development of pharmacogenomics.

Original languageEnglish (US)
Title of host publicationAdvances in Experimental Medicine and Biology
Pages220-231
Number of pages12
Volume630
DOIs
StatePublished - 2008

Publication series

NameAdvances in Experimental Medicine and Biology
Volume630
ISSN (Print)00652598

Fingerprint

Pharmacogenetics
Tamoxifen
Breast Neoplasms
Cytochrome P-450 CYP2D6
Aromatase Inhibitors
Aromatase
Therapeutics
Selective Estrogen Receptor Modulators
Hydroxylation
Chemotherapy
DNA sequences
Audition
United States Food and Drug Administration
Metabolites
Drug-Related Side Effects and Adverse Reactions
Pharmaceutical Preparations
Labeling
Hearing
Genes
Parents

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Weinshilboum, R. M. (2008). Pharmacogenomics of endocrine therapy in breast cancer. In Advances in Experimental Medicine and Biology (Vol. 630, pp. 220-231). (Advances in Experimental Medicine and Biology; Vol. 630). https://doi.org/10.1007/978-0-387-78818-0_14

Pharmacogenomics of endocrine therapy in breast cancer. / Weinshilboum, Richard M.

Advances in Experimental Medicine and Biology. Vol. 630 2008. p. 220-231 (Advances in Experimental Medicine and Biology; Vol. 630).

Research output: Chapter in Book/Report/Conference proceedingChapter

Weinshilboum, RM 2008, Pharmacogenomics of endocrine therapy in breast cancer. in Advances in Experimental Medicine and Biology. vol. 630, Advances in Experimental Medicine and Biology, vol. 630, pp. 220-231. https://doi.org/10.1007/978-0-387-78818-0_14
Weinshilboum RM. Pharmacogenomics of endocrine therapy in breast cancer. In Advances in Experimental Medicine and Biology. Vol. 630. 2008. p. 220-231. (Advances in Experimental Medicine and Biology). https://doi.org/10.1007/978-0-387-78818-0_14
Weinshilboum, Richard M. / Pharmacogenomics of endocrine therapy in breast cancer. Advances in Experimental Medicine and Biology. Vol. 630 2008. pp. 220-231 (Advances in Experimental Medicine and Biology).
@inbook{b3968ada1e424a9bb3589093b3df88c7,
title = "Pharmacogenomics of endocrine therapy in breast cancer",
abstract = "The treatment of breast cancer with selective estrogen receptor modulators such as tamoxifen and with aromatase inhibitors represents a major advance in cancer chemotherapy. However, there are large variations among patients in both the therapeutic efficacy and side effects of these drugs. Pharmacogenomics is the study of the role of inheritance in this variation and genetic variation in tamoxifen response represents one of the most striking examples of the potential clinical importance of pharmacogenomics. Tamoxifen requires {"}metabolic activation{"} catalyzed by cytochrome P450 2D6 (CYP2D6) to form hydroxylated metabolites-4-hydroxytamoxifen and endoxifen (N-desmethyl-4-hydroxytamoxifen)- both of which are much more potent than is the parent drug. However, CYP2D6 is genetically polymorphic. Approximately 5-8{\%} of Caucasian subjects are CYP2D6 {"}poor metabolizers{"} on a genetic basis and, as a result, are relatively unable to catalyze tamoxifen hydroxylation. These same subjects appear to have poorer outcomes when treated with tamoxifen than do CYP2D6 {"}extensive metabolizers{"}. These data led the US Food and Drug Administration (FDA) to hold public hearings in 2006 on the inclusion of this pharmacogenomic information in tamoxifen labeling. However, a series of important questions still remains to be addressed with regard to tamoxifen pharmacogenomics. There have also been preliminary attempts to study the pharmacogenomics of aromatase inhibitors, including the application of a genotype-to-phenotype research strategy designed to explore the nature and extent of common DNA sequence variation in the CYP19 gene that encodes aromatase. Those results-together with our current level of understanding of tamoxifen pharmacogenomics-will be reviewed in this chapter and both will be placed within the context of the overall development of pharmacogenomics.",
author = "Weinshilboum, {Richard M}",
year = "2008",
doi = "10.1007/978-0-387-78818-0_14",
language = "English (US)",
isbn = "9780387788173",
volume = "630",
series = "Advances in Experimental Medicine and Biology",
pages = "220--231",
booktitle = "Advances in Experimental Medicine and Biology",

}

TY - CHAP

T1 - Pharmacogenomics of endocrine therapy in breast cancer

AU - Weinshilboum, Richard M

PY - 2008

Y1 - 2008

N2 - The treatment of breast cancer with selective estrogen receptor modulators such as tamoxifen and with aromatase inhibitors represents a major advance in cancer chemotherapy. However, there are large variations among patients in both the therapeutic efficacy and side effects of these drugs. Pharmacogenomics is the study of the role of inheritance in this variation and genetic variation in tamoxifen response represents one of the most striking examples of the potential clinical importance of pharmacogenomics. Tamoxifen requires "metabolic activation" catalyzed by cytochrome P450 2D6 (CYP2D6) to form hydroxylated metabolites-4-hydroxytamoxifen and endoxifen (N-desmethyl-4-hydroxytamoxifen)- both of which are much more potent than is the parent drug. However, CYP2D6 is genetically polymorphic. Approximately 5-8% of Caucasian subjects are CYP2D6 "poor metabolizers" on a genetic basis and, as a result, are relatively unable to catalyze tamoxifen hydroxylation. These same subjects appear to have poorer outcomes when treated with tamoxifen than do CYP2D6 "extensive metabolizers". These data led the US Food and Drug Administration (FDA) to hold public hearings in 2006 on the inclusion of this pharmacogenomic information in tamoxifen labeling. However, a series of important questions still remains to be addressed with regard to tamoxifen pharmacogenomics. There have also been preliminary attempts to study the pharmacogenomics of aromatase inhibitors, including the application of a genotype-to-phenotype research strategy designed to explore the nature and extent of common DNA sequence variation in the CYP19 gene that encodes aromatase. Those results-together with our current level of understanding of tamoxifen pharmacogenomics-will be reviewed in this chapter and both will be placed within the context of the overall development of pharmacogenomics.

AB - The treatment of breast cancer with selective estrogen receptor modulators such as tamoxifen and with aromatase inhibitors represents a major advance in cancer chemotherapy. However, there are large variations among patients in both the therapeutic efficacy and side effects of these drugs. Pharmacogenomics is the study of the role of inheritance in this variation and genetic variation in tamoxifen response represents one of the most striking examples of the potential clinical importance of pharmacogenomics. Tamoxifen requires "metabolic activation" catalyzed by cytochrome P450 2D6 (CYP2D6) to form hydroxylated metabolites-4-hydroxytamoxifen and endoxifen (N-desmethyl-4-hydroxytamoxifen)- both of which are much more potent than is the parent drug. However, CYP2D6 is genetically polymorphic. Approximately 5-8% of Caucasian subjects are CYP2D6 "poor metabolizers" on a genetic basis and, as a result, are relatively unable to catalyze tamoxifen hydroxylation. These same subjects appear to have poorer outcomes when treated with tamoxifen than do CYP2D6 "extensive metabolizers". These data led the US Food and Drug Administration (FDA) to hold public hearings in 2006 on the inclusion of this pharmacogenomic information in tamoxifen labeling. However, a series of important questions still remains to be addressed with regard to tamoxifen pharmacogenomics. There have also been preliminary attempts to study the pharmacogenomics of aromatase inhibitors, including the application of a genotype-to-phenotype research strategy designed to explore the nature and extent of common DNA sequence variation in the CYP19 gene that encodes aromatase. Those results-together with our current level of understanding of tamoxifen pharmacogenomics-will be reviewed in this chapter and both will be placed within the context of the overall development of pharmacogenomics.

UR - http://www.scopus.com/inward/record.url?scp=49649086756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49649086756&partnerID=8YFLogxK

U2 - 10.1007/978-0-387-78818-0_14

DO - 10.1007/978-0-387-78818-0_14

M3 - Chapter

SN - 9780387788173

VL - 630

T3 - Advances in Experimental Medicine and Biology

SP - 220

EP - 231

BT - Advances in Experimental Medicine and Biology

ER -